Seagen Inc.
2023
$43.0B
Why
Pfizer acquired Seagen for approximately $43 billion in December 2023 to secure leadership in antibody-drug conjugate technology, the fastest-growing drug modality in oncology. Seagen's four commercially approved ADC products—Adcetris, Padcev, Tivdak, and Tukysa—provided immediate revenue contribution while the ADC platform technology provided the foundation for Pfizer's oncology pipeline strategy through 2030. The acquisition represented Pfizer's response to the anticipated loss of exclusivity on Ibrance and the broader need to establish a new oncology platform capable of generating multi-billion-dollar revenues independent of CDK4/6 inhibitor franchise sustainability.
Impact
The Seagen acquisition added approximately $3.2 billion in combined revenues in fiscal year 2024, with Padcev (enfortumab vedotin) as the fastest-growing contributor at approximately $1.7 billion. The ADC platform has generated multiple late-stage clinical development programs across different tumor types and combination regimens that are expected to provide regulatory submissions through 2027-2028. Pfizer's combined oncology portfolio now rivals AstraZeneca and Merck as one of the three largest commercial oncology businesses globally.
Outcome
The Seagen acquisition is still in its early commercial integration phase and final financial outcome will not be assessable until 2028-2030, when the late-stage ADC pipeline results are known and the revenue trajectory becomes clearer. The acquisition was financed through approximately $31 billion in new debt, creating ongoing interest expense that weighs on near-term earnings. Whether the $43 billion price—which represented approximately 20x Seagen's trailing revenues—is justified will depend on clinical trial success rates and commercial uptake of ADC indications beyond currently approved uses.